Navigation Links
Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709

ounting for approximately 4.5 million medical visits per year in the USA alone and resulting in annualised treatment costs in excess of USD8 billion.

About inhaled antibiotics

Inhaled antibiotics have so far been primarily used in the setting of Cystic Fibrosis or in the prophylaxis of Pneumocystis jiroveci. However, because they deliver high drug concentrations at the site of infection with negligible systemic absorption, they are the logical complements to standard intravenous therapy for severe nosocomial pneumonias and in the treatment of severe healthcare-associated pneumonia caused by multiresistant organisms.

About Human Microdosing

Human Microdosing involves the administration of sub-pharmacological doses of candidate drugs to human subjects without extensive animal testing. The Microdosing / "first-in-man" approach was pioneered by Xceleron and is now accepted as a valuable tool in drug screening. Use of the innovative "first-in-man" / Human Microdose concept allows companies to gain key information 12-18 months faster than using the conventional drug development paradigm.

About Arpida Ltd.

Arpida is a biopharmaceutical company with research facilities near Basel, Switzerland and in the USA. It focuses on the discovery and development of novel antibiotic drugs that seek to overcome the growing problem of bacterial resistance.

Arpida's leading product candidate is intravenous iclaprim, a broad-spectrum antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). In November 2006, intravenous iclaprim has successfully completed its first Phase III trial in the treatment of cSSSI (complicated skin and skin structure infections). In March 2007, patient enrolment into the Phase III programme was completed. The US Food and Drug Administration has granted fast track status to intravenous iclaprim for the treatment of cSSSI.


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Arpida adds novel antibiotic AR-2474 to its preclinical pipeline
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Arpida Announces Promising Results First Man Studies With
(Date:7/10/2014)... Calif. , July 10, 2014 Integrated ... leader in advanced memory and analog IC solutions, today ... on Thursday, July 24, 2014, at 7:00 a.m. Pacific ... financial results for the fiscal 2014 third quarter ended ... call via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific ...
(Date:7/10/2014)... July 10, 2014   Ventana Medical Systems, Inc. ... it has entered into an agreement with Merck KGaA, ... EMD Serono in the United States ... with Merck KGaA,s biopharmaceutical division on the development and ... target using Ventana,s proprietary diagnostic assays. In alignment with ...
(Date:1/15/2014)... MILTON, N.Y. , Jan. 15, 2014 Sono-Tek Corporation ... three months ended November 30, 2013, compared to sales of ... or 20%. Once again, this quarter has also shown growth ... in the first quarter of this fiscal year. Markets that ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... IRIDEX Corporation (Nasdaq: IRIX ) today reported ... Revenues were $10.8 million, gross margins were 45.4% ... of 2011 compared to guidance of $10 million, 45%, and ... the third quarter of 2011 and 7% in the nine ...
... an increased need by customers for support and education ... chain-wide effort to increase its pharmacy expertise in the ... diabetes specialists, announced Effie Steele, clinical services manager for ... community pharmacist is an important first line of defense ...
Cached Medicine Technology:IRIDEX Reports 2011 Third Quarter and Nine-Month Results 2IRIDEX Reports 2011 Third Quarter and Nine-Month Results 3IRIDEX Reports 2011 Third Quarter and Nine-Month Results 4IRIDEX Reports 2011 Third Quarter and Nine-Month Results 5Meijer Launches Diabetes Education Initiative in All 197 Pharmacies, Trains More Than 200 Pharmacists to Be Diabetes Specialists 2Meijer Launches Diabetes Education Initiative in All 197 Pharmacies, Trains More Than 200 Pharmacists to Be Diabetes Specialists 3
(Date:7/11/2014)... 11, 2014 This is a ... of the Cholesterol industry in Global and China. ... industry, including definitions, applications and industry chain structure. ... are provided with a focus on history, developments, ... comparison between the international and Chinese situation is ...
(Date:7/11/2014)... 2014 The International Concussion Organization ... the Best Buy Theater in Times Square, New ... the growing concussion epidemic that is plaguing athletes ... of competition. , The Symposium gathers more than ... coaches, professional athletes and legal scholars for engaging ...
(Date:7/11/2014)... This morning(July 9th, 2014 at 8 am), Dr. George ... illegal immigration crisis at our southern border and his recent ... Flinn told Good Morning Memphis host Ernie Freeman, “I saw ... is that they do not have enough agents to take ... coming into the border; the border isn’t protected.” , When ...
(Date:7/11/2014)... July 11, 2014 Even the hot Texas ... Godley Elementary School . The school had previously ... playground equipment from APCPLAY, but recently asked for an ... , Godley Elementary School chose a Rectangular Shade ... shelter for children on their playground. The shade measures ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 ASHBURN PSYCHOLOGICAL AND ... effect, which allows individuals with an intellectual disability or autism ... their licenses and ID cards to alert law enforcement or ... condition. The idea was inspired by a central Virginia ... protecting her 9 year old autistic son, JP. During ...
Breaking Medicine News(10 mins):Health News:Cholesterol Industry 2014 Development Trends in Global & China Regions in a New Research Study Available at DeepResearchReports.com 2Health News:Cholesterol Industry 2014 Development Trends in Global & China Regions in a New Research Study Available at DeepResearchReports.com 3Health News:The International Concussion Organization 501(c)(3) hosts its 1st Annual Concussion Symposium at the Best Buy Theater in Time Square, NYC, July 17th, 2014. 2Health News:Senate Candidate, George Flinn on Fox13 NEWS About the Border Crisis 2Health News:Cool Fun Under the Texas Sun: Godley Elementary School Purchases Shade Structure from APCPLAY© 2Health News:Recent Special “Autism” Code on Virginia Driver’s Licenses and ID Cards Goes into Law: Helpful or Discriminatory for Individuals on the Autistic Spectrum? 2Health News:Recent Special “Autism” Code on Virginia Driver’s Licenses and ID Cards Goes into Law: Helpful or Discriminatory for Individuals on the Autistic Spectrum? 3
... at settling a long-standing question among doctors has found that ... patients avoid recurrent strokes. Many doctors suspected that Warfarin was ... both views, showing the two drugs are equals in both ... and blood clots are involved in the final stages of ...
... immunodeficiency virus is a retrovirus that binds to receptors found ... a cell, the virus is internalized, copied into DNA, then ... of the host DNA. In many cases, the inserted viral ... more years. AIDS or Acquired Immune Deficiency Syndrome is a ...
... uterus, the more likely she is to have a miscarriage, ... Journal of Medicine details the most precise information the timing ... its success or failure. ,Fertilised eggs can attach themselves ... 12 days after ovulation, the researchers from the National Institute ...
... too soon is more likely to produce stressed-out toddlers ... targets for three to five-year olds could lead to ... than achieve accelerated learning, says the report. ... early start to their schooling and may revert to ...
... risks,say the researchers.Traditional student digs with mouldy and damp ... ,A study of over 20,000 Finnish students found that ... of asthma, but left residents with a greater chance ... damp houses were found to need more antibiotics than ...
... a virus is possibly resposible for infertility.The virus is ... of testicular tissue taken from men whose semen was ... more frequently than in those with normal semen. ... Heidelberg, which conducted the research, said the virus should ...
Cached Medicine News:Health News:More about HIV 2Health News:More about HIV 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: